
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci is a leading AI-powered synthetic biology company with an innovative approach to biologic drug discovery and cell line development, supported by strong preclinical and human ex vivo biopsy data. The company's lead drug candidate, ABS-201, has shown promising results in promoting hair growth and is well-tolerated with a potential dosing regimen of 2-3 injections over a 6-month period, making it a potential best-in-class option in the lucrative hair growth space. With a strong pipeline, high-profile partnerships, and a unique business model supporting downstream revenue potential, we see Absci as a potential >$5B market cap company in the longer-term.
Bears say
Absci is a biotechnology company that specializes in using AI and wet lab technologies to create novel biologics, with their lead product candidate being an anti-prolactin receptor antibody for AGA. While they have increased their projected peak revenue for this product, they will likely require additional funding for their clinical trials and there is no guarantee that their current partnerships will continue to contribute revenues. The potential for success is promising, but the uncertainty surrounding their financing and partnerships may pose a risk for investors.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares